Beijing Hanmi Pharmaceutical Co., Ltd., Mamiai, was established in 1996, one of the top ten brands of probiotics, and is a large-scale modern pharmaceutical company invested by South Korea's Hanmi Group and Beijing Zizhu
Beijing Hanmi Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmi) is the first modern pharmaceutical company invested by South Korea in China, established in March 1996 in the beautiful Shunyi Airport Development Zone, Beijing, covering an area of 13,600 square meters. Beijing Hanmi is a pharmaceutical company jointly invested and established by Hanmi Group and Beijing Zizhu Pharmaceutical Co., Ltd. (hereinafter referred to as Zizhu Pharmaceutical).
In addition to the headquarters, Hanmi Beijing also has a research center, a GMP factory, and a nationwide sales team. Among them, the GMP plant was jointly designed and built by the Korea Art Construction Design Institute and the Jilin Provincial Pharmaceutical Design Institute of China in strict accordance with the GMP standards, and passed the GMP certification of the State Drug Administration in December 2001 and was officially put into operation. The research center covers an area of nearly 4,000 square meters, including biological laboratory, chemical synthesis laboratory and pharmacology and toxicology laboratory, and is equipped with a variety of world-class drug research equipment. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China. In 2008, Beijing Hanmi established a "Business Center" with a new look, which integrates "R&D, production and sales", which has become a new milestone in its development history. In order to further strengthen the development of new drugs, the R&D center has been established, and it works closely with the Korea R&D Center, Hanmi Pharmaceutical Headquarters, Hanmi Fine Chemical Plant and Formula R&D Center to form an advanced and high-end global R&D network.
The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields, and the main products are more than a dozen varieties such as Mamiai, Yitanjing, Meichangan, Lidong, Aceclofenac, Ruimai, Libaiting, etc. Among them, Mamiai and Yi Tanjing have become the basic standing medicines for Chinese children, and are well received by doctors and parents of children.
Beijing Hanmi has successively won the "Pharmaceutical Market Integrity Demonstration Unit", "Trustworthy Brand of Children's Medicine in the Pharmaceutical Market", "Beijing High-tech Enterprise", "G20 Biomedical Industry Leapfrog Development Project", "Top 100 Regional Economy" in Shunyi District, "Advanced Enterprise in District Guaranteed Growth", "Large Taxpayer", "Advanced Unit of Financial Management", "Advanced Unit of Labor and Employment" and "Excellent Trade Union".
By 2020, Hanmi Pharma aims to develop more than 100 heavyweight new products and expand its drug categories to the fields of respiratory, digestive system, cancer treatment, and hypertension, with annual sales of 5 billion yuan.
For the sake of human life, we need to produce better medicines. In order to realize the common ideal, we will work tirelessly. For the sake of social progress and personal progress, we will do our best. As the first modern pharmaceutical company invested by South Korea in China, our company has taken a successful step in China. In the future, we will devote ourselves to the production of more high-quality, high-tech drugs, and make our greatest contribution to the country's pharmaceutical industry.
